Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mereo BioPharma Group plc - American Depositary Shares (NQ:MREO)

0.3229 +0.0111 (+3.56%)
Streaming Delayed Price Updated: 10:59 AM EDT, Jun 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mereo BioPharma Group plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Liquidia, Shake Shack And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
MicroMarvel: Mereo BioPharma - Analysts Favorite ↗
Mereo BioPharma develops therapeutics for oncology and rare diseases, with strong buy recommendations and price targets between $4 and $5. 
Via Talk Markets
News headline image
Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Why Streamline Health Solutions Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Uber To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Why Oracle Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but issued a weak forecast for the first quarter. 
Via Benzinga
News headline image
Booz Allen Hamilton Posts Upbeat Results, Joins AppFolio, Gentex And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday. 
Via Benzinga
Topics Stocks
News headline image
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Why Is Mereo BioPharma Stock Trading Higher Today? ↗
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) released interim data from the Phase 2 portion of the Phase 2/3 Orbit  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
It's time to start off the week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
News headline image
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.; Mereo Biopharma
Via GlobeNewswire
News headline image
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.